Testing a 5-fraction Simultaneous Integrated Boost in Radiotherapy for Breast Cancer: The UK FAST-Forward Boost Trial Opens to Recruitment
- PMID: 40768931
- DOI: 10.1016/j.clon.2025.103908
Testing a 5-fraction Simultaneous Integrated Boost in Radiotherapy for Breast Cancer: The UK FAST-Forward Boost Trial Opens to Recruitment
Conflict of interest statement
Conflict of Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: FAST-Forward Boost Trial Management Team reports financial support was provided by the National Institute for Health and Care Research. JB declares research grants to the Institute of Cancer Research Clinical Trials and Statistics Unit from Astra Zeneca, Merck Sharp & Dohme, Puma Biotechnology, Pfizer, Janssen-Cilag, Novartis, Eli Lilly, Breast Cancer Now, Breast International Group, Glaxo Smith Kline, Kortuc, Cancer Research UK, NIHR EME and Verastem. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Publication types
LinkOut - more resources
Full Text Sources